NCT05393986View on ClinicalTrials.gov

Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

August 4, 2022

Primary Completion Date

June 30, 2023

Study Completion Date

December 30, 2024

Conditions
Gastric AdenocarcinomaPancreatic CancerGastroesophageal Junction Adenocarcinoma
Interventions
DRUG

CT048 Autologous Injection (CT048)

up to 3 times CT048 Autologous Injection infusion

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing, China, Beijing

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Peking University

OTHER